MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User…...
VF Announces 2020 V-RED Award Winners
Two winners tied for first place and one received an honorable mention in the Vasculitis Foundation’s (VF) 2020 Recognizing Excellence in Diagnostics (V-RED) award program. Now in its seventh year, the program calls on patients worldwide to nominate a medical professional they want to recognize for making a critical, early…...
VF Announces Young Investigator Award
Dragana Odobasic, PhD, a research fellow at Monash University in Melbourne, Australia, was awarded the Vasculitis Foundation’s (VF) “Dr. Chris Cox-Marinelli Young Investigator Award” in May for her study, Tolerogenic Dendritic Cells for Antigen-Specific Immunosuppression in MPO-ANCA Vasculitis. The award, a one-year grant totaling $49,822, was created in memory of…...
Penn’s Giant Cell Arteritis Fast-Track Program Provides Rapid Evaluation
The tricky part of giant cell arteritis (GCA) is the need for rapid evaluation, given the high risk of rapid vision loss and the importance of getting appropriate diagnostic tests, such as a temporal artery biopsy, soon after starting treatment. Unfortunately, there are not a lot of outpatient programs that…...
The OHSU Vasculitis Center: Specializing in Multidisciplinary Care
The most common form of vasculitis in adults over the age of 50 is giant cell arteritis (GCA), an inflammation of the blood vessels that primarily affects the head—especially the temples and scalp—but also arteries in other parts of the body, including the aorta. Early diagnosis is critical in GCA…...
